CSIMarket
 


Concert Pharmaceuticals Inc   (CNCE)
Other Ticker:  
 

Concert Pharmaceuticals Inc 's Working Capital Ratio

CNCE's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




CNCE Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 44.74 % 86.39 % 81.65 % 58.38 % 63.13 %
Y / Y Current Assets Change 39.22 % 21.91 % -7.34 % 5.33 % -17.2 %
Working Capital Ratio MRQ 9.03 10.03 7.61 9.33 9.39
Overall Ranking # # # # #
Seq. Current Liabilities Change 7.67 % 7.15 % -6.44 % 34.1 % 38.65 %
Seq. Current Assets Change -3.03 % 41.26 % -23.66 % 33.14 % -15.1 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 9.03 above Concert Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry Concert Pharmaceuticals Inc booked the highest Working Capital Ratio than Concert Pharmaceuticals Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is CNCE most successful ?
Working Capital Ratio CNCE on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Concert Pharmaceuticals Inc 's Current Liabilities $ 17 Millions Visit CNCE's Balance sheet
Concert Pharmaceuticals Inc 's Current Assets $ 157 Millions Visit CNCE's Balance sheet
Source of CNCE's Sales Visit CNCE's Sales by Geography


Cumulative Concert Pharmaceuticals Inc 's Working Capital Ratio

CNCE's Working Capital Ratio for the trailling 12 Months

CNCE Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 44.74 % 86.39 % 81.65 % 58.38 % 63.13 %
Y / Y Current Assets TTM Growth 39.22 % 21.91 % -7.34 % 5.33 % -17.2 %
Working Capital Ratio TTM 9.02 9.1 9.85 11.53 13.08
Total Ranking TTM # 436 # 614 # 583 # 521 # 348
Seq. Current Liabilities TTM Growth 7.67 % 7.15 % -6.44 % 34.1 % 38.65 %
Seq. Current Assets TTM Growth -3.03 % 41.26 % -23.66 % 33.14 % -15.1 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $17.40 millions, average cumulative Working Capital Ratio decreased to 9.02 below the Concert Pharmaceuticals Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 164 other companies have achieved higher Working Capital Ratio than Concert Pharmaceuticals Inc . While Working Capital Ratio overall ranking has improved so far to 436, from total ranking in previous quarter at 172.

Explain Working Capital Ratio
Where is CNCE most successful ?
Working Capital Ratio CNCE on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 165
Healthcare Sector # 271
Within the Market # 436


TTM Working Capital Ratio Statistics
High Average Low
31.69 17.86 9.02
(Jun 30 2018)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Diamedica Therapeutics Inc   24.31 $ 36.490  Millions$ 1.501  Millions
Pasithea Therapeutics Corp   24.21 $ 44.469  Millions$ 1.837  Millions
Seres Therapeutics Inc   23.69 $ 247.513  Millions$ 10.449  Millions
Anaptysbio inc  23.15 $ 450.444  Millions$ 19.459  Millions
Dice Therapeutics Inc   22.96 $ 267.837  Millions$ 11.665  Millions
Pmv Pharmaceuticals Inc   22.75 $ 265.176  Millions$ 11.656  Millions
Eliem Therapeutics Inc   22.46 $ 133.171  Millions$ 5.928  Millions
Keros Therapeutics Inc   22.21 $ 245.875  Millions$ 11.070  Millions
Cassava Sciences Inc   22.06 $ 183.272  Millions$ 8.308  Millions
Janux Therapeutics Inc   21.08 $ 344.330  Millions$ 16.335  Millions
Ovid Therapeutics Inc   20.88 $ 140.537  Millions$ 6.732  Millions
Day One Biopharmaceuticals Inc   20.83 $ 380.513  Millions$ 18.271  Millions
Minerva Neurosciences Inc   20.41 $ 44.841  Millions$ 2.197  Millions
Lantern Pharma Inc   20.35 $ 62.020  Millions$ 3.047  Millions
Agios Pharmaceuticals Inc   19.54 $ 784.935  Millions$ 40.171  Millions
Forte Biosciences Inc   19.45 $ 44.594  Millions$ 2.293  Millions
Kura Oncology Inc   19.45 $ 436.391  Millions$ 22.441  Millions
Verve Therapeutics Inc   19.35 $ 561.630  Millions$ 29.018  Millions
Nuvalent Inc   18.90 $ 245.245  Millions$ 12.975  Millions
Catalyst Biosciences Inc   18.40 $ 30.246  Millions$ 1.644  Millions
Astria Therapeutics inc   18.40 $ 118.485  Millions$ 6.441  Millions
Stoke Therapeutics Inc   17.94 $ 264.601  Millions$ 14.749  Millions
Generation Bio Co   17.93 $ 310.558  Millions$ 17.318  Millions
Olema Pharmaceuticals inc   17.93 $ 225.058  Millions$ 12.552  Millions
Moonlake Immunotherapeutics  17.84 $ 88.539  Millions$ 4.962  Millions
Point Biopharma Global Inc   17.84 $ 296.231  Millions$ 16.608  Millions
Zomedica Corp   17.84 $ 127.103  Millions$ 7.126  Millions
Pardes Biosciences Inc   17.80 $ 214.041  Millions$ 12.028  Millions
Annovis Bio inc   17.60 $ 32.487  Millions$ 1.846  Millions
Akouos inc   17.30 $ 174.493  Millions$ 10.087  Millions

Date modified: 2022-11-08T16:42:48+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FACA's Profile

Stock Price

FACA's Financials

Business Description

Fundamentals

Charts & Quotes

FACA's News

Suppliers

FACA's Competitors

Customers & Markets

Economic Indicators

FACA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071